AbbVie (ABBV) has announced it will acquire Aliada Therapeutics in an all-cash deal for $1.4 billion, with the transaction expected to close by the end of this year.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Why Is ABBV Acquiring Aliada?
AbbVie’s interest in Aliada stems from its commitment to neuroscience as a primary growth area. This acquisition grants AbbVie access to Aliada’s lead compound, ALIA-1758, an antibody under development for treating Alzheimer’s disease.
Commenting on the acquisition, AbbVie’s EVP of R&D and Chief Scientific Officer, Roopal Thakkar, M.D., noted, “This acquisition immediately positions us to advance ALIA-1758, a potentially best-in-class disease-modifying therapy for Alzheimer’s disease. In addition, Aliada’s novel BBB [blood-brain barrier]-crossing technology strengthens our R&D capabilities to accelerate the development of next-generation therapies for neurological disorders.”
With Aliada’s blood-brain barrier-crossing technology now in its toolkit, AbbVie is positioned to develop more effective ways to deliver treatments directly to the brain. This capability marks a critical advance in addressing neurological conditions that were once challenging to treat.
Is ABBV Stock a Buy or Sell?
Analysts remain cautiously optimistic about ABBV stock, with a Moderate Buy consensus rating based on nine Buys, and seven Holds. Over the past year, ABBV has surged by more than 35%, and the average ABBV price target of $204.29 implies an upside potential of 8.2% from current levels.
